RNASEK and pancreatic adenocarcinoma: In the form of deep deletions, RNASEK was altered in nineteen types of cancer, with the highest rate observed in miscellaneous neuroepithelial tumors, where one case out of 31 (3.23%) was affected. Amplification was identified in eight types of cancer, including SARC, BLCA, OV epithelial tumor, esophagogastric cancer (ESCA), melanoma, endometrial cancer, PAAD, and glioma, with the highest rate detected in SARC, at four cases out of 255 (1.96%).